Ichnos Sciences has a mission to provide breakthrough therapies that will extend and improve lives. A clinical-stage biotech with the spirit of a start-up, Ichnos aims to shift the way the world thinks about innovation through its research and development of transformative bi/multispecific antibody therapies in oncology. Headquartered in New York, N.Y., Ichnos is using its patented BEAT® technology platform to advance a pipeline of drug candidates to treat hematologic cancers and solid tumors.
Ichnos Sciences aims to shift the way the world thinks about innovation in medicine by developing potentially transformative biologic treatments in immuno-oncology. Headquartered in New York City, Ichnos has research and manufacturing operations at two sites in Switzerland. Ichnos has strong capabilities in research, antibody engineering and clinical development of biologics. The first wave of Ichnos’ multispecific antibody pipeline targeting a range of hematologic malignancies are in phase 1/2.